These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3027338)

  • 21. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation.
    Meanwell NA; Roth HR; Smith EC; Wedding DL; Wright JJ; Fleming JS; Gillespie E
    J Med Chem; 1991 Sep; 34(9):2906-16. PubMed ID: 1654430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
    Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
    J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization.
    Lanza F; Beretz A; Stierlé A; Corre G; Cazenave JP
    Thromb Res; 1987 Mar; 45(5):477-84. PubMed ID: 3035738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of heterocycle condensed purines.
    Suzuki H; Yamamoto M; Shimura S; Miyamoto K; Yamamoto K; Sawanishi H
    Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1163-8. PubMed ID: 12237530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.
    Nagata K; Ogawa T; Omosu M; Fujimoto K; Hayashi S
    Arzneimittelforschung; 1985; 35(7):1034-6. PubMed ID: 2996562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphodiesterase inhibitors: their comparative effectiveness in vitro in various organs.
    Adachi K; Numano F
    Jpn J Pharmacol; 1977 Feb; 27(1):97-103. PubMed ID: 194077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
    Price B; Pyne NJ; Houslay MD
    Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
    Elks ML; Manganiello VC
    Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic AMP-phosphodiesterase IIIA1 inhibitors decrease cytosolic Ca2+ concentration and increase the Ca2+ content of intracellular storage sites in human platelets.
    Roevens P; de Chaffoy de Courcelles D
    Biochem Pharmacol; 1993 Jun; 45(11):2279-82. PubMed ID: 8390836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cyclic AMP phosphodiesterase activity of human blood platelet membrane by ADP.
    Kahn NN; Sinha AK
    Biochim Biophys Acta; 1989 Aug; 984(1):113-8. PubMed ID: 2548620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
    Juan-Fita MJ; Vargas ML; Hernández J
    Eur J Pharmacol; 2005 Apr; 512(2-3):207-13. PubMed ID: 15840406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
    Ruppert D; Weithmann KU
    Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
    Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
    Bandurco VT; Schwender CF; Bell SC; Combs DW; Kanojia RM; Levine SD; Mulvey DM; Appollina MA; Reed MS; Malloy EA
    J Med Chem; 1987 Aug; 30(8):1421-6. PubMed ID: 3039135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
    Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
    J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856).
    Venuti MC; Alvarez R; Bruno JJ; Strosberg AM; Gu L; Chiang HS; Massey IJ; Chu N; Fried JH
    J Med Chem; 1988 Nov; 31(11):2145-52. PubMed ID: 2846840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of blood platelet cAMP phosphodiesterase: a QSAR analysis.
    Tiwari S; Sharma RC; Ojha TN; Singh P
    Drug Des Discov; 1995 Jan; 12(3):249-58. PubMed ID: 7662831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
    Weishaar RE; Cain MH; Bristol JA
    J Med Chem; 1985 May; 28(5):537-45. PubMed ID: 2985781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor.
    Erhardt PW; Hagedorn AA; Sabio M
    Mol Pharmacol; 1988 Jan; 33(1):1-13. PubMed ID: 2826995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.